Skip to Content
  • How Much Action Should the FDA Take?

    Biocentury has a look at the issue of compounding pharmacies, which is an area that’s been getting a lot of attention in this era of steep rises in generi… Read More
  • This is the FDA’s Problem

    Here’s an article at JAMA that addresses the problem of off-patent (generic) medications in the US: they’ve traditionally been the cheapest in the i… Read More
  • Drug Costs, Real and Fake

    Here’s an interesting look at the price of a single orphan medication: the rattlesnake antivenom CroFab, which has already been held up as an example of … Read More
  • Shkreli’s Chagas Maneuver

    In case you’ve been wondering what Martin Shkreli has been up to, here’s a look at his recent appearance at a meeting put on by the folks at Forbes. Read More
  • A Look At Drug Pricing

    The Wall Street Journal ran a long look yesterday at drug pricing in the US, and it’s hard to argue with this summary: The upshot is Americans fund much o… Read More
  • Idiocy On Drug Research Costs

    Here’s a piece from the Center for Economic and Policy Research that claims to have the whole high-drug-price problem figured out. It’s “incr… Read More
  • What Martin Shkreli Is Counting On

    So now that a compounding pharmacy group is moving in on Martin Shkreli’s business model for Daraprim, he’s got problems, right? I would like to thi… Read More
  • Dying By the Sword

    There have been several developments in the T*ing/Valeant world, that supposedly risk-free gravy train where you wait for others to discover the drugs, then you… Read More
Page 3 of 1512345...10...Last »